ROTH MKM initiated coverage on Longeveron with a new price target
$LGVN
Biotechnology: Pharmaceutical Preparations
Health Care
ROTH MKM initiated coverage of Longeveron with a rating of Buy and set a new price target of $10.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/6/2024 | $10.00 | Buy | ROTH MKM |
| 1/5/2022 | $20.00 | Buy | EF Hutton |
MIAMI, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it has appointed Devin Blass as Chief Technology Officer (CTO) and Senior Vice President of Chemistry, Manufacturing, and Controls (CMC), effective December 2, 2024. In this role, he will lead the Company's technological and manufacturing strategies. "We are delighted to have Devin join Longeveron at this transformational time in the Company's evolution," said Wa'el Hashad, Chief Executive Officer at Longeveron. "This appointment reinforces Longevero
MIAMI, July 09, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, including hypoplastic left heart syndrome (HLHS) and Alzheimer's disease, today announced that Neha Motwani, a senior healthcare investment banker, has been elected to the Longeveron Board of Directors at the Company's recent Annual Meeting of Stockholders. "I am delighted to welcome Neha, with her tremendous healthcare industry experience, to the Board of Directors," said Joshua Hare, Co-founder, Chief Science Officer and Chairman of the Board at Longeveron. "Her exte
MIAMI, July 08, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that Roger Hajjar, MD, Director of the Gene and Cell Therapy Institute at Mass General Brigham, has been elected to the Longeveron Board of Directors. Dr. Hajjar is an internationally recognized scientist whose cardiac gene therapy discoveries have spurred clinical trials for heart failure, whose methodologies for cardiac-directed gene transfer are currently utilized by investigators around the world, and who was appointed as the inaugural director of the
ROTH MKM initiated coverage of Longeveron with a rating of Buy and set a new price target of $10.00
EF Hutton initiated coverage of Longeveron with a rating of Buy and set a new price target of $20.00
MIAMI, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will report third quarter 2024 financial results and provide a business update on Tuesday, November 12, 2024 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30 p.m. ET. Conference Call Details: Conference Call Number:1.877.407.0789Conference ID:13749428 Call me™ Feature:Click HereWebcast:Click Here An archived replay of the webcast will be available on the "Events & Presentations" se
MIAMI, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will report second quarter 2024 financial results and provide a business update on Wednesday, August 14, 2024 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30 p.m. ET. Conference Call Details: Conference Call Number:1.877.407.0789Conference ID:13747923Call me™ Feature:Click HereWebcast:Click Here An archived replay of the webcast will be available on the "Events & Presentations" sec
Phase 2b clinical trial evaluating Lomecel-BTM in rare pediatric disease HLHS on track for completing enrollment by end of 2024Data from Phase 2a clinical trial evaluating Lomecel-BTM in Alzheimer's Disease selected for Featured Research Oral Presentation at 2024 Alzheimer's Association International ConferenceCompleted two financings in April raising gross proceeds of $11.4 million to fund continued clinical developmentFocused expenditure management reduced first quarter Total Operating Expenses 8% year-over-yearCompany to host conference call and webcast today at 5:00pm ET MIAMI, May 14, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medi
8-K - Longeveron Inc. (0001721484) (Filer)
144 - Longeveron Inc. (0001721484) (Subject)
8-K - Longeveron Inc. (0001721484) (Filer)
4 - Longeveron Inc. (0001721484) (Issuer)
4 - Longeveron Inc. (0001721484) (Issuer)
4 - Longeveron Inc. (0001721484) (Issuer)
4 - Longeveron Inc. (0001721484) (Issuer)
4 - Longeveron Inc. (0001721484) (Issuer)
4 - Longeveron Inc. (0001721484) (Issuer)
SC 13G/A - Longeveron Inc. (0001721484) (Subject)
SC 13G - Longeveron Inc. (0001721484) (Subject)
SC 13G - Longeveron Inc. (0001721484) (Subject)
MIAMI, Feb. 19, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 79th Emerging Growth Conference on February 18 & 19, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 2 - TodayFebruary 19, 2025 Replay Day 1 here:https://emerginggrowt
Cellular therapy Lomecel-B™ has been granted an International Non-proprietary Name (INN) of "laromestrocel" on the INN List issued by the World Health Organization (WHO)Lomecel-B™ is a proprietary, scalable, allogeneic cellular therapy being evaluated in Alzheimer's disease and hypoplastic left heart syndrome (HLHS), a rare pediatric disease and orphan indicationLomecel-B™ first cellular therapeutic candidate to receive U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) designation for Alzheimer's disease MIAMI, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threat
MIAMI, Feb. 18, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 79th Emerging Growth Conference on February 18 & 19, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1February 18, 2025 9:30Virtual Lobby opens.Register for the Conference. If you already registered, go back to the